U.S. markets open in 1 hour 10 minutes
  • S&P Futures

    3,818.00
    -21.00 (-0.55%)
     
  • Dow Futures

    31,430.00
    -35.00 (-0.11%)
     
  • Nasdaq Futures

    12,503.50
    -160.25 (-1.27%)
     
  • Russell 2000 Futures

    2,186.90
    -2.80 (-0.13%)
     
  • Crude Oil

    65.50
    -0.59 (-0.89%)
     
  • Gold

    1,682.50
    -16.00 (-0.94%)
     
  • Silver

    25.02
    -0.27 (-1.06%)
     
  • EUR/USD

    1.1871
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    27.20
    -1.37 (-4.80%)
     
  • GBP/USD

    1.3847
    +0.0019 (+0.14%)
     
  • USD/JPY

    108.5910
    +0.2090 (+0.19%)
     
  • BTC-USD

    50,428.03
    -327.66 (-0.65%)
     
  • CMC Crypto 200

    1,019.89
    +76.71 (+8.13%)
     
  • FTSE 100

    6,620.94
    -9.58 (-0.14%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of IRTC, JFU and AZN

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 22, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

iRhythm Technologies, Inc. (NASDAQ:IRTC)

Investors Affected : August 4, 2020 - January 28, 2021

A class action has commenced on behalf of certain shareholders in iRhythm Technologies, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) iRhythm's business would suffer as a result of the CMS' rulemaking; (2) reimbursement rates would in fact plummet; (3) a lack of national pricing in the CMS rule and fee schedule would cause uncertainty and weakness in the Company's business; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times

Shareholders may find more information at https://securitiesclasslaw.com/securities/irhythm-technologies-inc-loss-submission-form/?id=13042&from=1

9F Inc. (NASDAQ:JFU)

Lawsuit on behalf of investors who purchased JFU securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company's August 14, 2019 initial public offering; and/or (2) between August 14, 2019 and September 29, 2020.

A class action has commenced on behalf of certain shareholders in 9F Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the purported value and benefits of the Company's financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and Property and Casualty Company Limited (“PICC”) had been engaged in an ongoing contractual dispute regarding payment of service fees under their cooperation agreement; (2) the collectability of service fees owed to 9F by PICC under the cooperation agreement was in doubt and at serious risk of non-payment; (3) there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; (4) as a result of the foregoing, the Company's platform, business model, reputation and financial results had been materially impaired; and (5) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/9f-inc-loss-submission-form/?id=13042&from=1

Astrazeneca Plc (NYSE:AZN)

Investors Affected : May 21, 2020 - November 20, 2020

A class action has commenced on behalf of certain shareholders in Astrazeneca Plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) initial clinical trials for the Company's COVID-19 vaccine, AZD1222, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (b) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (c) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (d) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (e) AstraZeneca's clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (f) as a result of (a)-(e) above, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (g) as a result of (a)-(f) above, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

Shareholders may find more information at https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form/?id=13042&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/631042/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-IRTC-JFU-and-AZN